

IN THE CLAIMS:

Please amend the claims as follows:

1. (Amended) A pharmaceutical antitumor composition which comprises:

extract of at least one of Pulsatillae Radix or extract of Ulmaceae cortex as active ingredients(s), prepared by extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae cortex, the amount of Pulsatillae Radix and Ulmaceae cortex being greater than 0%, in a solvent at a temperature of below 60°C; and

filtering and lyophilizing the extract.

2. (Amended) A pharmaceutical antitumor composition comprising:

over 30wt% of extract of at least one of Pulsatillae Radix or Ulmaceae as active ingredient(s); and

below 70wt% extract of Ginseng Radix and/or Glycyrrhizae Radix as auxiliary ingredient(s), prepared by extracting 30-70 wt% of powdered Pulsatillae Radix and powdered Ulmaceae cortex, the amount of the powdered Pulsatillae Radix and the powdered Ulmaceae cortex being greater than 0%, and by extracting 30-70wt% of powdered Ginseng Radix and 30-70% of powdered Glycyrrhizae Radix, the amount of the powdered Ginseng Radix and the powdered Glycyrrhizae Radix

being greater than 0%, in a solvent at a temperature of below 60°C, filtering and lyophilizing the extract.

3. (Amended) The pharmaceutical composition according to claims 1 or 2, wherein the solvent is water, alcohol, acetone, ethyl acetate or mixtures thereof and the composition is formulated as powder, granule, tablet, capsule, injectable powder or ointment.

4. (Amended) The pharmaceutical composition according to claims 1 or 2, wherein the auxiliaries are one or more selected from the group consisting of diluent, binding agent, disintegrator, preservative, indolent, isotonic agent and lubricant.

5. (Amended) A process for the preparation of a pharmaceutical antitumor composition, which comprises:

extracting 0-100wt% of powdered Pulsatillae Radix and 0-100wt% of powdered Ulmaceae cortex, the amount of the powdered Pulsatillae Radix and the powdered Ulmaceae cortex being greater than 0%, in a solvent at a temperature of below 60°C;

filtering; and

lyophilizing the extract.

6. (Amended) A process for the preparation of a pharmaceutical antitumor composition comprising over 30wt% of extract of

Pulsatillae Radix and/or extract of Ulmaceae cortex as active ingredient(s) and less than 70wt% of extract of Ginseng Radix and/or Glycyrrhizae Radix as auxiliary ingredients(s), which comprises:

extracting 30-70wt% of powdered Pulsatillae Radix and 30-70wt% of powdered Ulmaceae cortex, the amount of Pulsatillae Radix and Ulmaceae cortex being greater than 0%;

extracting 30-70wt% of powdered Ginseng Radix and 30-70 wt% of powdered Glycyrrhizae Radix, the amount of Ginseng Radix and Glycyrrhizae Radix being greater than 0%, in a solvent at a temperature of below 60°C;

filtering; and

lyophilizing the extract.

7. (Amended) The process according to claims 5 or 6, wherein the solvent is water, alcohol, acetone, ethyl acetate or mixtures thereof and the composition is formulated as powder, granule, tablet, capsule, injectable powder or ointment.

8. (Amended) The process according to claims 5 or 6, wherein the extract is mixed with at least one auxiliary selected from the group consisting of diluent, binding agent, disintegrator, preservative, indolent, isotonic agent and lubricant.

Please add the following claims:

--9. The pharmaceutical antitumor composition according to claim 1, wherein the composition is stable for at least 2 years.--

--10. The pharmaceutical antitumor composition according to claim 2, wherein the composition is stable for at least 2 years.--

--11. The process according to claim 5, wherein the composition is stable for at least 2 years.--

--12. The process according to claim 6, wherein the composition is stable for at least 2 years.--

Attached hereto is a marked-up version of the changes made to the application by this Amendment.